Answer the following questions in about 150 words each :
Analyze the impact of the TRIPS Agreement on the pricing and availability of generic drugs in the Indian pharmaceutical sector.
10 marks · answer in 150 words · directive: Analyze
The core of a good answer
TRIPS ended India's process-patent regime and so removed the legal basis for copying new patented medicines, which threatened prices and supply of new generics; India used the flexibilities TRIPS allows (Section 3(d) and compulsory licensing) to keep most medicines generic and cheap, so the effect has been felt mainly on new, patented drugs.
An outline written by upsc.help, not an official UPSC answer; every fact checked by a separate review. How we work
What the question asks
The question asks for an analysis of cause and effect: how the shift from the Patents Act, 1970 to a TRIPS-compliant regime changed the price and availability of generic drugs. A balanced answer shows both the pressure TRIPS created and the safeguards India built in, with named cases.
Answer outline
Introduction
The Patents Act, 1970 allowed only process patents for drugs, which let Indian firms reverse-engineer molecules and made India a large supplier of low-cost generics. TRIPS (1995) required product patents for pharmaceuticals, which India restored from 2005, when the transition period for developing countries ended.
Changes TRIPS forced
- Patents for pharmaceutical products, enforceable for at least 20 years (TRIPS Article 33).
- A mailbox for product patent applications with retrospective effect from 1995 and exclusive marketing rights (1999 amendment); full product patent protection from 2005.
- New molecules patented after 1995 can no longer be copied during the patent term, so their generics enter only after expiry or under a licence.
Effect on pricing and availability
- Drugs already on the market before 1995 stayed generic, so the bulk of India's essential medicines market was not affected.
- For new drugs, prices are set by patent holders and can be many times the generic price, as the imatinib (Glivec) case showed.
- Indian firms can still make and export off-patent generics, and new generics of patented molecules enter only after patent expiry or under a licence.
Flexibilities India used
- Section 3(d): new forms of known substances are not patentable unless they show enhanced efficacy, which blocks evergreening.
- Section 84(1) compulsory licences, available among other grounds where the patented invention is not available to the public at a reasonably affordable price.
- The Doha Declaration (2001) reaffirmed the sovereign right of WTO members to grant compulsory licences for pharmaceuticals and the aim of access to medicines for all.
Concerns
- Pressure for TRIPS-plus terms in bilateral and regional trade agreement negotiations.
- India granted its first compulsory licence only in March 2012, seven years after product patents returned.
Conclusion
TRIPS has raised the cost of new patented medicines, but India's use of its flexibilities has kept generic supply largely intact; the continuing task is to defend these flexibilities in trade talks.
Examples and data to cite
- Novartis v. Union of India (Supreme Court, 1 April 2013): patent for the beta crystalline form of imatinib (Glivec) refused under Section 3(d); Glivec cost about USD 2,666 per patient per month against USD 177 to 266 for generics.
- First compulsory licence, March 2012: Natco Pharma allowed to make sorafenib tosylate, a cancer drug patented by Bayer, under Section 84(1) of the Patents Act, 1970.
- Fourth WTO Ministerial Conference, Doha, 2001: Declaration on the TRIPS Agreement and Public Health.
- TRIPS Article 31bis (amendment allowing export under compulsory licence) entered into force on 23 January 2017.
Facts to remember
- TRIPS came into force on 1 January 1995; the transition period for developing countries expired in 2005.
- Patents (Amendment) Act, 1999 allowed transitional filing of product patent applications; full product patent protection returned in 2005.
- Section 3(d) of the Patents Act, 1970 took its present form in 2005, requiring a significant difference in efficacy.
- TRIPS Article 31 sets the conditions for compulsory licences.